The temporal relationship between drug supply indicators: an audit of international government surveillance systems. by Werb, Dan et al.
The temporal relationship between
drug supply indicators: an audit
of international government
surveillance systems
Dan Werb,1 Thomas Kerr,1 Bohdan Nosyk,2 Steffanie Strathdee,3 Julio Montaner,2
Evan Wood1
To cite: Werb D, Kerr T,
Nosyk B, et al. The temporal
relationship between
drug supply indicators: an
audit
of international government
surveillance systems. BMJ
Open 2013;3:e003077.
doi:10.1136/bmjopen-2013-
003077
▸ Prepublication history for
this paper is available online.
To view these files please
visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2013-003077).
Received 18 April 2013
Revised 16 July 2013
Accepted 19 July 2013
1Urban Health Research
Initiative, BC Centre for
Excellence in HIV/AIDS,
Vancouver, Canada
2BC Centre for Excellence in
HIV/AIDS, Vancouver, Canada
3University of California San
Diego, Institute of the
Americas, La Jolla, California,
USA
Correspondence to
Dr Evan Wood;
uhri-ew@cfenet.ubc.ca
ABSTRACT
Objectives: Illegal drug use continues to be a major
threat to community health and safety. We used
international drug surveillance databases to assess the
relationship between multiple long-term estimates of
illegal drug price and purity.
Design:We systematically searched for longitudinal
measures of illegal drug supply indicators to assess the
long-term impact of enforcement-based supply reduction
interventions.
Setting: Data from identified illegal drug surveillance
systems were analysed using an a priori defined protocol
in which we sought to present annual estimates
beginning in 1990. Data were then subjected to trend
analyses.
Main outcome measures: Data were obtained from
government surveillance systems assessing price, purity
and/or seizure quantities of illegal drugs; systems with at
least 10 years of longitudinal data assessing price, purity/
potency or seizures were included.
Results:We identified seven regional/international
metasurveillance systems with longitudinal measures of
price or purity/potency that met eligibility criteria. In the
USA, the average inflation-adjusted and purity-adjusted
prices of heroin, cocaine and cannabis decreased by
81%, 80% and 86%, respectively, between 1990 and
2007, whereas average purity increased by 60%, 11%
and 161%, respectively. Similar trends were observed in
Europe, where during the same period the average
inflation-adjusted price of opiates and cocaine
decreased by 74% and 51%, respectively. In Australia,
the average inflation-adjusted price of cocaine decreased
14%, while the inflation-adjusted price of heroin and
cannabis both decreased 49% between 2000 and 2010.
During this time, seizures of these drugs in major
production regions and major domestic markets
generally increased.
Conclusions:With few exceptions and despite
increasing investments in enforcement-based supply
reduction efforts aimed at disrupting global drug supply,
illegal drug prices have generally decreased while drug
purity has generally increased since 1990. These findings
suggest that expanding efforts at controlling the global
illegal drug market through law enforcement are failing.
OBJECTIVES
The United Nations (UN) recently estimated
that the global illegal drug trade is worth at
least US$350 billion annually,1 and illegal drug
use remains a major threat to community
health and safety.2 3 In addition to the range
of harm associated with the direct health
effects of drugs, including fatal overdose,4 5
illegal drug use is also one of the key global
drivers of blood-borne disease transmission, in
particular HIV infection.6 7 Illegal drug
markets also contribute to community con-
cerns, such as high rates of violence in settings
where the trade proliferates.8
In response to the health and social con-
cerns associated with illegal drug use, several
UN conventions were organised to control the
possession, consumption and manufacture of
illegal drugs.9–11 As a result, during the last
ARTICLE SUMMARY
Article focus
▪ Studies have demonstrated that illegal drug use
remains a threat to community health and safety.
▪ However, less is known regarding the long-term
impact of efforts to reduce the overall supply of
illegal drugs.
Key messages
▪ Using longitudinal governmental surveillance data,
this study demonstrates that during the past two
decades, the supply of major illegal drugs has
increased, as measured through a general decline
in the price and a general increase in the purity of
illegal drugs in a variety of settings.
Strengths and limitations of this study
▪ This study was limited by the quality and consist-
ency of surveillance data on illegal drug supply.
▪ This study presents data on trends in illegal drug
supply in a variety of settings during two decades,
including consumer and export drug markets.
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several decades, most national drug control strategies have
prioritised drug law enforcement interventions to reduce
drug supply, despite recent calls by experts to explore alter-
native models of drug control, such as systems of drug
decriminalisation and legal regulation.12–14 Some unin-
tended consequences of this approach, such as record
incarceration rates, have been well documented.15–18 In
addition, a small number of studies assessing aspects of
drug supply, measured through indicators of drug price,
purity/potency and seizures, have been undertaken to
describe the global relationship between these indicators
over the long term.19 However, systematic evaluation of
these relationships is still needed to elucidate patterns of
drug supply. The present study, therefore, sought to sys-
tematically identify international data from publicly avail-
able illegal drug surveillance systems to assess long-term
estimates of illegal drug supply.
DESIGN
Outcomes of interest
The primary outcomes of interest were long-term pat-
terns of illegal drug supply, measured through indicators
of price and purity/potency for three major illegal
drugs: cannabis, cocaine and opiates (eg, opium and
heroin). While data on amphetamine-type stimulants
exist in some countries (eg, the UK), this class of drugs
was not included given inconsistent data collection and
classiﬁcation, and ﬂuctuating surveillance periods and
overall data quality. A secondary outcome of interest was
data on illegal drug seizures in (1) major illegal drug
source regions and, (2) major destination markets, as
identiﬁed by the United Nations Ofﬁce on Drugs and
Crime (UNODC).20 These secondary outcome data
were used as an additional proxy measure to assess the
availability of illegal drugs in speciﬁc regions, as has
been carried out previously.21 22 All outcomes were sys-
tematically identiﬁed through publicly available illegal
drug surveillance systems. Linear-by-linear association
trend tests were carried out on annual estimates of all
outcomes of interest. Price and purity estimates repre-
sent median values for each year, while estimates for sei-
zures represent crude totals of quantity seized. All price
estimates are expressed in 2011 USD and are, where pos-
sible, adjusted for purity.23
Illegal drug surveillance systems
An online search of surveillance systems monitoring
illegal drugs using two a priori deﬁned inclusion criteria
was carried out. Search terms included the following:
drugs, illicit, illegal, price, purity, potency, surveillance
system, government data, longitudinal, annual, estimate.
Inclusion/exclusion criteria were as follows: only surveil-
lance systems that included continuous longitudinal
assessments of these outcomes of interest for at least
10 years were included because we speciﬁcally sought to
assess the long-term impact of enforcement-based supply
reduction strategies on illegal drug price and purity/
potency. Finally, data extraction was restricted to 1990
and onwards to focus on patterns of supply during
recent decades.
Data were obtained through online searches of regis-
tries of surveillance systems (eg, governmental websites,
UN databases), governmental reports and peer-reviewed
publications, through referrals from experts in the ﬁeld,
and through data requests to relevant organisations
including the UNODC. All authors had complete access
to all data and all had ﬁnal responsibility to submit for
publication. Ethics approval was not required given that
we relied exclusively on publicly available data.
RESULTS
We identiﬁed seven government surveillance systems
that met inclusion criteria. Of these, 3 (43%) reported
on international data, 3 (43%) on data from the USA
and 1 (14%) on data from Australia. One of the longest
running surveillance system identiﬁed, the US-based
Marijuana Potency Monitoring Project, is funded by the
US National Institutes of Health and was established in
1975, while the most recent surveillance system was
established in 2001 (eg, the US-based National Drug
Threat Assessment). With respect to international surveil-
lance systems, the UNODC administers two separate sur-
veillance systems that collect data from all participating
UN member states: the Annual Reports Questionnaire
surveillance system that collects price and purity/
potency data, and the Drug Seizures Database that col-
lects seizure data. Finally, the European Monitoring
Centre for Drugs and Drug Addiction administers the
Reitox drug surveillance system network, which aggre-
gates data from several country-level surveillance systems
in Europe, as described below.24
Price and purity/potency
Table 1 presents surveillance systems that matched
search criteria. An assessment of data provided by these
surveillance systems demonstrated several broad trends.
First, purity and/or potency of illegal drugs generally
remained stable or increased overall during the study
period. Second, the price of illegal drugs, with few
exceptions, generally decreased. Third, seizures of can-
nabis, cocaine and opiates generally increased in major
drug production regions and major domestic markets.
Figure 1 presents data from the US Drug Enforcement
Administration’s System To Retrieve Information from
Drug Evidence (STRIDE). As can be seen, between 1990
and 2007 (the last year for which data are publicly avail-
able), the purity of heroin and cocaine, and the potency
of cannabis herb in the US increased, while the
inﬂation-adjusted and purity-adjusted retail street prices
of these three drugs declined.25 Speciﬁcally, heroin
purity increased by 60% (p=0.568), cocaine purity
increased by 11% (p=0.181) and cannabis herb potency
increased by 161% (p<0.001) during this time. During
the same period, the prices of heroin, cocaine and
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Table 1 Major illegal drug data surveillance systems
Surveillance system
Country/
region
Inception
date
Illegal drugs considered Outcomes considered
Summary of findingsCannabis Cocaine Heroin Price Purity Use Seizures
University of Mississippi
Marijuana Project
USA 1975– X X Cannabis potency increased between 1990 and 2009
STRIDE Surveillance
System
USA 1986– X X X X X Price decreased and purity/potency increased across all
illegal drugs considered
UNODC
Drug Seizures Database International 1980– X X X X Seizures of all drugs have increased between 1995 and
2006
UNODC Annual Reports
Questionnaire
International 1990– X X X X X X Prices of opiates, cocaine, and cannabis have generally
decreased in Europe and the USA while purity and potency
have increased
Reitox (EMCDDA
database)
Europe 1993– X X X X X Price of all illegal substances decreased in 2002–2007.
Cocaine, cannabis and heroin seizures increased between
2002 and 2007
Illicit Drug Reporting
System
Australia 2000– X X X X X X Between 2000 and 2010, the price of cocaine, cannabis and
heroin decreased, while perceived purity remained stable
National Drug Threat
Assessment
USA 2001– X X X X X Between 2005 and 2009, cocaine purity decreased whereas
price increased
EC, European Commission; EMCDDA, European Monitoring Centre For Drugs and Drug Addiction; EU, European Union; STRIDE, System To Retrieve Information from Drug Evidence;
UNODC, United Nations Office of Drug Control.
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cannabis decreased 81% (p<0.001), 80% (p<0.001) and
86% (p<0.001), respectively.
Figure 2 presents data collected by the UNODC on the
street price of cocaine and opiates in participating
European countries (ie, Austria, Belgium, Denmark,
Finland, France, Germany, Greece, Italy, Luxembourg,
Netherlands, Norway, Iceland, Portugal, Spain, Sweden,
Switzerland, UK and Ireland).26 In these countries,
between 1990 and 2009, the aggregate average retail street
price of cocaine decreased by 51%, from US$198/g to US
$98/g (p<0.001). Similarly, the aggregate average price of
opiates in Europe decreased 74%, from a high of US
$295/g in 1990 to US$77/g in 2009 (p<0.001).
Data from the Australian Illicit Drug Reporting System
(IDRS) were available from 2000 to 2010. IDRS data
suggest that the price of illegal drugs in Australia ﬂuctu-
ated substantially during this period. Speciﬁcally, after
adjustment, the price of heroin decreased by 49%, from
approximatelyUS$460/g to approximately US$235/g
(p<0.001), despite the well-described heroin ‘drought’ of
2001,27 which saw a reduction in the supply and availability
of heroin in Australia. Additionally, the price of cocaine
decreased 14% from approximately $A255/g to $A220/g
(p=0.477), and the price of cannabis decreased 49% from
approximately $A25/g to $A13/g (p<0.001).28
Seizures
Domestic markets
Figure 3 presents data on cannabis and cocaine seizures
in the USA between 1990 and 2010. As shown, data from
the US Drug Enforcement Administration’s STRIDE sur-
veillance system demonstrate that the amount of canna-
bis herb seized by the Drug Enforcement Administration
both in, and destined for, the USA increased 465%,
from approximately 130 000 kg in 1990 to approximately
720 000 kg in 2010 (p<0.001). During this same period,
despite ﬂuctuations, the amount of cocaine seized by
the US Drug Enforcement Administration decreased
49%, from approximately 57 000 kg in 1990 to 29 000 in
2010 (p=0.409), whereas the amount of heroin seized
increased 29% from approximately 535 kg in 1990 to
690 kg (p=0.979, heroin seizure data not shown).29
Figure 4 presents data on cannabis, cocaine and
heroin seizures in countries participating in the
European Monitoring Centre for Drugs and Drug
Addiction’s Reitox surveillance network (ie, European
Union member countries, as well as Croatia, Norway and
Turkey), between 1995 and 2009. As can be observed,
annual estimates of the quantity of both cocaine and
cannabis herb seized ﬂuctuated throughout this period;
however, the quantity of heroin seized increased rela-
tively steadily. Speciﬁcally, the number of kilograms of
cannabis herb seized was at a low of approximately
57 000 kg in 1995, and peaked 1 year later in 1996 at
approximately 138 000 kg (p=0.446). The number of
cocaine seizures was at a low of approximately 21 000 kg
in 1995, and peaked at approximately 121 000 kg in
2006 (p=0.018). Finally, the number of kilograms of
heroin seized increased 380% from a low of approxi-
mately 5000 in 1995 to a high of approximately 24 000
in 2009 (p<0.001).
Production regions
With respect to opiate seizures, the Golden Triangle
includes parts of Thailand, Laos, Vietnam and Myanmar,
and according to the UNODC, this region is the second
largest supplier of heroin globally, although production
has declined throughout the last decade, with opium
production decreasing by approximately 60% and 90%
Figure 1 Estimated price and purity of heroin, cocaine and
cannabis in the USA, 1990–2009.
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in Myanmar and Laos, respectively.30 In this region,
trends in seizures of opium have ﬂuctuated; 3198 kg of
opium were seized in 1990, with a high of 12 462 kg
seized in 2007 before a steep decline to 1225 kg in 2010
(p=0.856). Similarly, seizures of heroin ﬂuctuated, with a
decrease of more than half, from 1337 kg in 1990, to
627 kg in 2010 (p=0.085), and a peak of 1565 kg seized
in 2009. In Afghanistan, which is believed to supply
more than 90% of the world’s opium,30 seizures of raw
and prepared opium increased by more than 12 000%,
from 453 kg in 1990 to 57 023 kg in 2010, and seizures
of heroin increased by more than 600%, from 1256 kg
in 1990 to 9036 kg in 2010 (note: missing data prevented
a trend test for annual opium and heroin seizures in
Afghanistan).
With respect to cocaine seizures, according to the
UNODC, Latin America’s Andean region, which includes
Peru, Bolivia and Colombia, is the primary global supplier
of this drug, as coca leaf is grown exclusively in this
region.31 While seizures of cocaine in the Andean region
decreased 81%, from 97 437 kg in 1990 to 17 835 kg in
2007 (p=0.028), seizures of coca leaf increased 188% from
601 038 kg in 1990 to 1.73 million kilograms in 2007
(p=0.004). During the same period, the area of coca
Figure 3 Cocaine and cannab is seizures in the USA, 1990–2010.
Figure 2 Average inflation-adjusted price of opiates and cocaine in Europe, 1990–2007.
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cultivation in this region declined slightly, from approxi-
mately 210 000 to 180 000 ha (p=0.004).
Finally, according to the UNODC, major areas of can-
nabis cultivation exist in North Africa, Afghanistan and
North America. These areas are net exporters of canna-
bis, although most cannabis-producing countries also
produce the drug for internal consumption.20 In North
Africa (ie, Algeria, Morocco and Tunisia), seizures of
cannabis herb increased by 208% from 67 930 kg in
1990 to 209 445 kg in 2007 (p=0.015). In North America
(ie, Canada, the USA and Mexico), seizures of cannabis
herb increased by 288% from 782 607 kg in 1990 to 3.05
million kilograms in 2007 (p<0.001). In Afghanistan,
while data on cannabis herb seizures are not available,
seizures of cannabis resin increased 630% from 5068 kg
in 1990 to 36 972 kg in 2006 (p=0.061).
CONCLUSIONS
Longitudinal data from government surveillance systems
demonstrate that during the past two decades there has
been a general pattern of increased illegal drug supply as
deﬁned through lower price and higher purity of heroin,
cocaine and cannabis. During the same period, patterns
of drug seizures either increased or remained stable,
although the trends detected in some of these indicators
did not reach statistical signiﬁcance. As such, we conclude,
consistent with previous studies,19 that the global supply of
illicit drugs has likely not been reduced in the previous
two decades. In particular, the data presented in this study
suggest that the supply of opiates and cannabis, in particu-
lar, have increased, given the increasing potency and
decreasing prices of these illegal commodities. These
results have implications for the development of evidence-
based drug policies, particularly given the interest in novel
drug policy approaches in a number of settings in Latin
America, North America and Europe.32–34
As noted elsewhere,35 36 there are limitations of eco-
logical analyses based on international surveillance
systems. First, some states collect little or no data on indi-
cators of illegal drug supply, whereas other states spend
signiﬁcant energy on monitoring drug availability.
Second, even in states that closely track indicators of
supply, the degree to which seized samples of illegal
drugs reﬂect purity of retail drugs sold on the street is
subject to variation, though where possible we presented
purity-adjusted prices to address this limitation.23
Nevertheless, the long-term trends in increasing purity
and decreasing price presented here likely reﬂect the
overall trends in many regions, though it should be
noted that in some regions (eg, Europe), indicators of
price and purity may have been strongly inﬂuenced by a
few countries such as the UK and Spain. In addition,
some exceptions in the trends were observed. Australia
for instance, while experiencing a signiﬁcant decrease in
the prices of heroin as well as cannabis, did not experi-
ence a signiﬁcant decrease in the price of cocaine,
which may reﬂect the geographic isolation of the region
or other market factors. It is also of note that Australia’s
‘heroin drought’,37 which saw a sudden drop in mea-
sures of the supply and availability of heroin, appears to
have had a limited long-term impact on supply, though
some experts suggest that it may have resulted in higher
levels of polysubstance use among Australian heroin
Figure 4 Cocaine, cannabis and heroin seizures in Europe*, 1990–2010.
6 Werb D, Kerr T, Nosyk B, et al. BMJ Open 2013;3:e003077. doi:10.1136/bmjopen-2013-003077
Open Access
injectors.27 Third, limitations in longitudinal data collec-
tion precluded our ability to include amphetamine-type
stimulants and other emerging synthetic substances, as
this data is limited to certain countries and the focus of
this study was on regional trends. It is noteworthy in this
regard that the production of synthetic substances—as
well as indoor cannabis cultivation—present particular
challenges for supply reduction strategies, given that
these drugs can be mass produced in clandestine loca-
tions regardless of climate or other factors that limit
traditional drug production.20 38 Finally, while this
review focused on patterns of price and purity of
selected illegal drugs, these measures are only a marker
of drug supply and do not measure other factors deter-
mining availability and concomitant rates of drug use.
These limitations in assessing global drug supply using
classic proxy measures such as price, purity and, to a
lesser extent, seizures, suggest that there may be a need
to expand the range of measures systematically collected
by governments and international bodies such as the
UNODC and the European Monitoring Centre for
Drugs and Drug Addiction. In particular, meaningfully
incorporating measures derived from street-level ques-
tionnaires of people who use drugs may provide a more
reliable metric of supply and availability. Indeed, some
bodies, such as Australia’s IDRS, collect such data,28 and
this methodological approach should be considered by
those coordinating surveillance of illegal drugs. Other
bodies have also prioritised emphasising measures of
community health including reduced HIV infections,
reduced drug-related violence and reductions in
number of individuals incarcerated.39 40
In summary, longitudinal illegal drug surveillance
systems demonstrate a general global pattern of falling
drug prices and increasing drug purity and potency,
alongside a relatively consistent pattern of increasing sei-
zures of illegal drugs. Although source data have limita-
tions and there are some exceptions to these trends,
these ﬁndings should be useful given the current
debates and drug policy experimentation under way in
Latin America, North America and Europe.32–34 It is
hoped that this study highlights the need to re-examine
the effectiveness of national and international drug strat-
egies that place a disproportionate emphasis on supply
reduction at the expense of evidence-based prevention
and treatment of problematic illegal drug use.
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